MannKind Corporation (MNKD)
MNKD Stock Price Chart
Explore MannKind Corporation interactive price chart. Choose custom timeframes to analyze MNKD price movements and trends.
MNKD Company Profile
Discover essential business fundamentals and corporate details for MannKind Corporation (MNKD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jul 2004
Employees
403.00
Website
https://www.mannkindcorp.comCEO
Michael E. Castagna
Description
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Financial Timeline
Browse a chronological timeline of MannKind Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $109.18m.
Earnings released on 6 May 2026
EPS came in at -$0.05 falling short of the estimated -$0.02 by -150.00%, while revenue for the quarter reached $90.17m , missing expectations by -14.43%.
Earnings released on 26 Feb 2026
EPS came in at -$0.05 falling short of the estimated -$0.01 by -400.00%, while revenue for the quarter reached $111.96m , beating expectations by +14.74%.
Earnings released on 5 Nov 2025
EPS came in at $0.03 surpassing the estimated $0.01 by +200.00%, while revenue for the quarter reached $82.13m , missing expectations by -17.75%.
Earnings released on 6 Aug 2025
EPS came in at $0.00 falling short of the estimated $0.04 by -94.65%, while revenue for the quarter reached $76.53m , missing expectations by -4.53%.
Earnings released on 8 May 2025
EPS came in at $0.04 surpassing the estimated $0.03 by +33.33%, while revenue for the quarter reached $78.35m , missing expectations by -0.11%.
Earnings released on 26 Feb 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $76.78m , beating expectations by +2.40%.
Earnings released on 7 Nov 2024
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $70.08m , missing expectations by -6.40%.
Earnings released on 7 Aug 2024
EPS came in at $0.05 surpassing the estimated -$0.03 by +249.93%, while revenue for the quarter reached $72.39m , beating expectations by +11.69%.
Earnings released on 8 May 2024
EPS came in at $0.04 surpassing the estimated $0.03 by +53.85%, while revenue for the quarter reached $66.26m , beating expectations by +9.54%.
Earnings released on 27 Feb 2024
EPS came in at $0.02 , while revenue for the quarter reached $58.47m , beating expectations by +9.13%.
Earnings released on 7 Nov 2023
EPS came in at $0.02 surpassing the estimated $0.01 by +160.76%, while revenue for the quarter reached $51.25m , beating expectations by +1.05%.
Earnings released on 7 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -47.38%, while revenue for the quarter reached $48.61m , beating expectations by +13.18%.
Earnings released on 9 May 2023
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $40.63m , beating expectations by +8.63%.
Earnings released on 23 Feb 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $36.06m , beating expectations by +1.57%.
Earnings released on 8 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $32.83m , beating expectations by +28.80%.
Earnings released on 9 Aug 2022
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $18.89m , beating expectations by +20.93%.
Earnings released on 5 May 2022
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $11.99m , beating expectations by +13.33%.
Earnings released on 24 Feb 2022
EPS came in at -$0.11 falling short of the estimated -$0.06 by -83.33%, while revenue for the quarter reached $12.52m , missing expectations by -26.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $22.21m , beating expectations by +7.72%.
Earnings released on 11 Aug 2021
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $23.28m , beating expectations by +33.10%.
MNKD Stock Performance
Access detailed MNKD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
